NorthWest Biotherapeutics Inc (NWBO)

[reachjo]

Good morning Mr. Cloughsey,

On the Clinical Trial Options website there is a slide titled “ExpressPoints: Applying Precision Medicine in Glioblastoma: New and Emerging Therapeutic Targets.” It incorrectly states DCVax as a failure. On another slide titled "Late-stage failures with Immunotherapies in Glioblastoma" includes “Dendritic cell vaccine DCVax-L phase 3.”

The success of the trial was presented at the New York Academy of Sciences conference on May 10. The data shows both endpoints met statistical significance confirming DCVax to be a success. Would you kindly look into this and make appropriate changes to the deck where necessary. UCLA is a beacon for GBM patients to turn to for accurate and confirmed information on successful treatments for this horrible disease.

Thank you for your consideration and time reading this email.

Regards,